ski 2053r

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

SKI 2053R: structure in first source; RN given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	6918271
MeSH ID	M0239684

Synonyms (6)

Synonym
AC-2111
ski-2053r
nsc-644591
ski 2053r
AKOS015964850
[(4r,5r)-5-(aminomethyl)-2-propan-2-yl-1,3-dioxolan-4-yl]methanamine;platinum;propanedioic acid

Research Excerpts

Actions

Excerpt	Reference	Relevance
"SKI 2053R did not cause significant neurotoxicity or mucositis."	( A Phase I study of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-1,3-dioxolane] platinum(II) in patients with advanced malignancies. Bang, YJ; Cho, YB; Heo, DS; Kim, DK; Kim, KH; Kim, NK; Kim, TY; Lee, JA; Park, YI; Shin, SG, 2001)	1.03

Treatment

Excerpt	Reference	Relevance
"In SKI 2053R-treated groups, the time required for a mean tumor weight of 1,000 mg was 33.1 days in KATO III xenografts and 35.0 days in WiDr xenografts as compared with 30.2 and 27.2 days in CDDP-treated groups, respectively."	( Antitumor activity of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2- isopropyl-1,3-dioxolane]platinum(II), a new platinum analogue, as an anticancer agent. Ahn, JS; Cho, YB; Hong, WS; Kim, DK; Kim, HT; Kim, KH; Kim, TS; Tai, JH, 1995)	0.81

Toxicity

Excerpt	Reference	Relevance
" The results show that SKI 2053R is embryotoxic at a minimally maternally toxic dose in rats."	( Embryotoxic effects of SKI 2053R, a new potential anticancer agent, in rats. Chung, MK; Kim, JC; Roh, JK, )	0.75
"Heptaplatin is a newly developed platinum derivative which has been reported to be less toxic than cisplatin."	( Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer. Ahn, JH; Bahng, H; Chang, HM; Kang, WC; Kang, YK; Kim, TW; Kim, WK; Lee, JS; Park, JS, 2002)	0.31
" Measures to more effectively prevent nephrotoxicity should be developed for the safe use of heptaplatin."	( Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer. Ahn, JH; Bahng, H; Chang, HM; Kang, WC; Kang, YK; Kim, TW; Kim, WK; Lee, JS; Park, JS, 2002)	0.31
"The present study was conducted to test the possible teratogenic and toxic effects of anti-cancer drug heptaplatin (SKI 2053) on developing embryos and fetuses in gestating SWR/J mice."	( Embryo-feto-toxicity of anticancer drug, heptaplatin in laboratory mice. Abdel-Samad, MF; Abou-Tarboush, FM; Al-Ahmadi, BA; Al-Anazi, KM; Al-Faifi, MY; Farah, MA, 2010)	0.36

Compound-Compound Interactions

Excerpt	Reference	Relevance
" Overall, the present study supports the clinical development of HTP in combination with low-dose PTX against HNSCC."	( Anti-tumor activity of heptaplatin in combination with 5-fluorouracil or paclitaxel against human head and neck cancer cells in vitro. Cho, YB; Kim, SY; Kuh, HJ; Lee, JW; Lee, SH; Park, JK, 2006)	0.33

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	9 (47.37)	18.2507
2000's	5 (26.32)	29.6817
2010's	5 (26.32)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.10

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	11.10 (24.57)
Research Supply Index	3.26 (2.92)
Research Growth Index	4.36 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (11.10)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	4 (19.05%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	17 (80.95%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
fluorouracil Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.	4.1	3	1	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic
metoclopramide Metoclopramide: A dopamine D2 antagonist that is used as an antiemetic.. metoclopramide : A member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine.	3.39	1	1	benzamides; monochlorobenzenes; substituted aniline; tertiary amino compound	antiemetic; dopaminergic antagonist; environmental contaminant; gastrointestinal drug; xenobiotic
ondansetron Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.	3.39	1	1	carbazoles
platinum Platinum: A heavy, soft, whitish metal, resembling tin, with atomic number 78, atomic weight 195.084, symbol Pt. It is used in manufacturing equipment for laboratory and industrial use. It occurs as a black powder (platinum black) and as a spongy substance (spongy platinum) and may have been known in Pliny's time as alutiae.	2.17	1	0	elemental platinum; nickel group element atom; platinum group metal atom
camptothecin NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source	2.1	1	0	delta-lactone; pyranoindolizinoquinoline; quinoline alkaloid; tertiary alcohol	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; genotoxin; plant metabolite
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	2.03	1	0	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
irinotecan [no description available]	2.1	1	0	carbamate ester; delta-lactone; N-acylpiperidine; pyranoindolizinoquinoline; ring assembly; tertiary alcohol; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 5.99.1.2 (DNA topoisomerase) inhibitor; prodrug
carboplatin [no description available]	2.7	3	0
nedaplatin nedaplatin: structure given in first source	2.17	1	0

Condition	Relationship Strength	Studies	Trials
Cancer of Colon [description not available]	2.42	2	0
Colonic Neoplasms Tumors or cancer of the COLON.	2.42	2	0
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	2.42	2	0
Adenocarcinoma, Basal Cell [description not available]	4.86	4	2
Leukocytopenia [description not available]	4.36	2	2
Cancer of Stomach [description not available]	5.04	5	2
Emesis [description not available]	3.39	1	1
Acute Disease Disease having a short and relatively severe course.	3.39	1	1
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	4.86	4	2
Kidney Diseases Pathological processes of the KIDNEY or its component tissues.	4.36	2	2
Leukopenia A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000).	4.36	2	2
Proteinuria The presence of proteins in the urine, an indicator of KIDNEY DISEASES.	3.39	1	1
Stomach Neoplasms Tumors or cancer of the STOMACH.	5.04	5	2
Vomiting The forcible expulsion of the contents of the STOMACH through the MOUTH.	3.39	1	1
Carcinoma, Epidermoid [description not available]	2.02	1	0
Cancer of Larynx [description not available]	2.02	1	0
Cancer of Lung [description not available]	4.3	4	1
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	2.02	1	0
Laryngeal Neoplasms Cancers or tumors of the LARYNX or any of its parts: the GLOTTIS; EPIGLOTTIS; LARYNGEAL CARTILAGES; LARYNGEAL MUSCLES; and VOCAL CORDS.	2.02	1	0
Lung Neoplasms Tumors or cancer of the LUNG.	4.3	4	1
Cancer of Head [description not available]	2.03	1	0
Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)	2.03	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	1.98	1	0
Leukemia L 1210 [description not available]	1.98	1	0
Leukemia P388 An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.	1.98	1	0
Carcinoma, Oat Cell [description not available]	3.38	1	1
Blood Diseases [description not available]	3.38	1	1
Hematologic Diseases Disorders of the blood and blood forming tissues.	3.38	1	1
Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.	3.38	1	1
Carcinoma, Small Cell An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)	3.38	1	1
Acute Liver Injury, Drug-Induced [description not available]	3.39	1	1
Benign Neoplasms [description not available]	3.39	1	1
Thrombopenia [description not available]	3.39	1	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	3.39	1	1
Thrombocytopenia A subnormal level of BLOOD PLATELETS.	3.39	1	1
Chemical and Drug Induced Liver Injury A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.	3.39	1	1

chemdatabank.com